Cutaneous Adverse Events to Type I BRAF Inhibitors: An Analysis of Effects Associated with Each Inhibitor and Therapeutic Time Interval to Onset

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

(2013) L. Boussemart et al.   ANNALS OF ONCOLOGY

Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

(2013) M. E. Lacouture et al.   ONCOLOGIST

RASopathic Skin Eruptions during Vemurafenib Therapy

(2013) Jeannine D. Rinderknecht et al.   PLoS One

Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem

(2013) Viswanath Reddy Belum et al.   Current Oncology Reports

Squamoproliferative Lesions Arising in the Setting of BRAF Inhibition

(2012) Nathan T. Harvey et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

Unusual Complication of Vemurafenib Treatment of Metastatic Melanoma: Exacerbation of Acantholytic Dyskeratosis Complicated by Kaposi Varicelliform Eruption

(2012) Monique Gupta et al.   ARCHIVES OF DERMATOLOGY

Photodynamic Therapy for Multiple Eruptive Keratoacanthomas Associated With Vemurafenib Treatment for Metastatic Melanoma

(2012) Allireza Alloo   ARCHIVES OF DERMATOLOGY

Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management

(2012) Lisa Zimmer   ARCHIVES OF DERMATOLOGY

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

(2012) R.M. Anforth et al.   BRITISH JOURNAL OF DERMATOLOGY

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities

(2012) R. Sinha et al.   BRITISH JOURNAL OF DERMATOLOGY

Eruptive Squamous Cell Carcinomas Associated with BRAF-Inhibitor Therapy in a Patient with Metastatic Melanoma

(2012) Navid Ezra et al.   DERMATOLOGIC SURGERY

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition

(2012) Lisa Zimmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

(2012) Emily Y. Chu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

Cutaneous toxicities of RAF inhibitors

(2012) Rachael Anforth et al.   LANCET ONCOLOGY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vemurafenib in Melanoma with BRAF V600E Mutation

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY